Found: 14
Select item for more details and to access through your institution.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
- Published in:
- BMC Infectious Diseases, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12879-023-08298-6
- By:
- Publication type:
- Article
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 11, p. 1453, doi. 10.1177/1352458517726381
- By:
- Publication type:
- Article
Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 6, p. 805, doi. 10.1177/1352458517708464
- By:
- Publication type:
- Article
Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
- Published in:
- Multiple Sclerosis Journal, 2017, v. 23, n. 7, p. 995, doi. 10.1177/1352458516684023
- By:
- Publication type:
- Article
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
- Published in:
- Journal of Neuroinflammation, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12974-023-02900-z
- By:
- Publication type:
- Article
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 7, p. 880, doi. 10.1001/jamaneurol.2021.1364
- By:
- Publication type:
- Article
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.
- Published in:
- Frontiers in Neurology, 2022, v. 13, p. 1, doi. 10.3389/fneur.2022.1032830
- By:
- Publication type:
- Article
The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis.
- Published in:
- Frontiers in Neurology, 2022, v. 13, p. 1, doi. 10.3389/fneur.2022.907245
- By:
- Publication type:
- Article
Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis.
- Published in:
- Annals of Neurology, 2023, v. 93, n. 1, p. 103, doi. 10.1002/ana.26534
- By:
- Publication type:
- Article
Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation.
- Published in:
- 2019
- By:
- Publication type:
- Letter
Vaccination responses in B‐cell‐depleted multiple sclerosis patients: The role of drug pharmacokinetics.
- Published in:
- European Journal of Neurology, 2022, v. 29, n. 11, p. 3137, doi. 10.1111/ene.15529
- By:
- Publication type:
- Article
Suppressed IgG4 class switching in dupilumab‐ and TNF inhibitor‐treated patients after mRNA vaccination.
- Published in:
- Allergy, 2024, v. 79, n. 7, p. 1952, doi. 10.1111/all.16089
- By:
- Publication type:
- Article